PERK inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
US11104651B2 · kind B2 · utility
0Cited by
0References
20Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 5, 2020 |
| Grant date | Aug 31, 2021 |
| Priority date | — |
| Expiry date | Jul 5, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds represented by Formula I are disclosed herein,wherein R, Ra and R1-R14 are as defined herein. Further disclosed are uses and methods utilizing said compounds for use in inhibiting an activity of PERK, and in treating a disease or disorder associated with aggregation-prone proteins, a disease or disorder in which downregulating an unfolded protein response is beneficial, and/or Huntington's disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.